^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Small Cell Squamous Cancer

    Related cancers:
    1d
    IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (clinicaltrials.gov)
    P2, N=70, Recruiting, Innate Pharma | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • IPH5201
    1d
    TITANS: A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) (clinicaltrials.gov)
    P=N/A, N=440, Recruiting, BeOne Medicines
    New trial • HEOR • Real-world evidence
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab-jsgr)
    7d
    NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P2, N=33, Terminated, NeoImmuneTech | N=83 --> 33 | Active, not recruiting --> Terminated; sponsor decision (not for safety)
    Enrollment change • Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Tecentriq (atezolizumab) • Hyleukin-7 (efineptakin alfa)
    8d
    UNIFIER: Universal Immunization to Fortify Immunotherapy Efficacy and Response (clinicaltrials.gov)
    P2, N=500, Not yet recruiting, University of Florida | Phase classification: P2/3 --> P2 | N=1200 --> 500
    Phase classification • Enrollment change • IO biomarker
    8d
    Severe IL-6-dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report. (PubMed, Front Oncol)
    We report a 72-year-old man with stage IV squamous NSCLC harboring an EGFR mutation and PD-L1 tumor proportion score of 90% who developed persistent fever shortly after first exposure to ivonescimab combined with nab-paclitaxel and carboplatin. His prior treatments included concurrent chemoradiotherapy, osimertinib, the investigational EGFR inhibitor BH-30643, afatinib, and recent gamma knife for cerebellar metastases plus palliative radiotherapy for bone metastases...Symptoms improved with corticosteroids, tocilizumab, and desmopressin, consistent with probable arginine vasopressin deficiency (AVP-D), possibly secondary to hypophysitis-though pituitary metastasis cannot be ruled out without biopsy...Advanced age, EGFR-mutant/PD-L1-high tumor biology, recent radiotherapy, and Parkinsonism may have contributed to the inflammatory environment, though none can be proven causal in a single case and each deserves prospective study. Early recognition of persistent steroid-responsive fever, serial IL-6 monitoring, thorough endocrine workup, and timely IL-6 blockade are critical.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IL6 (Interleukin 6)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Gilotrif (afatinib) • carboplatin • albumin-bound paclitaxel • Actemra IV (tocilizumab) • Idafang (ivonescimab)
    9d
    A Study of HDM2020 in Patients With Advanced Sq-NSCLC (clinicaltrials.gov)
    P1, N=150, Recruiting, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
    New P1 trial
    10d
    Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (clinicaltrials.gov)
    P2, N=120, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    10d
    Nebulized AER101 in Pre-op NSCLC (clinicaltrials.gov)
    P1, N=5, Not yet recruiting, University of Oklahoma
    New P1 trial
    10d
    SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • Enshuxing (enlonstobart) • SYS6010
    11d
    Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France. (PubMed, Cancer Med)
    This real-world study demonstrates the low frequency of HER2 testing and potential poor prognosis for patients diagnosed with LAM HER2m NSCLC in France between 2015 and 2020. Despite the low prevalence of HER2m NSCLC, these data highlight the importance of routine HER2 testing to enable patients with HER2m NSCLC to receive treatments that can improve clinical outcomes.
    Clinical data • Retrospective data • Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation
    14d
    PRAD2: Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Anhui Provincial Cancer Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    14d
    Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets (clinicaltrials.gov)
    P2, N=158, Not yet recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: Oct 2031 --> Apr 2032 | Initiation date: Apr 2026 --> Nov 2026 | Trial primary completion date: Jan 2031 --> Jan 2032
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Idafang (ivonescimab)